Form 4: ELDER WILLIAM ROBERT reports acquisition/exercise transactions in CRVO

Rhea-AI Filing Summary

ELDER WILLIAM ROBERT reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ELDER WILLIAM ROBERT

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO, GC & Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.8	02/11/2026		A		30,000		(1)	02/11/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.

	/s/ William R. Elder	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CervoMed (CRVO) report for William Robert Elder?

CervoMed reported that CFO, GC & Secretary William Robert Elder received a grant of 30,000 stock options on February 11, 2026. These options give him the right to buy CervoMed common stock under the company’s equity compensation arrangements, subject to a multi‑year vesting schedule.

How many CervoMed (CRVO) stock options were granted in this Form 4?

The Form 4 shows a grant of 30,000 stock options to William Robert Elder. These options are derivative securities on CervoMed common stock and bring his directly owned derivative holdings to 30,000 following the reported transaction on February 11, 2026.

What is the exercise price of William Robert Elder’s CervoMed (CRVO) stock options?

The stock options granted to William Robert Elder have an exercise price of $4.8 per share. This means he can purchase CervoMed common stock at $4.8 for each option when vested and exercisable, regardless of the market price at that future time.

When do the newly granted CervoMed (CRVO) stock options start vesting?

The options start vesting on February 28, 2026. The underlying common shares vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month, continuing over a total 36‑month period, according to the Form 4 footnote.

Over what period will William Robert Elder’s CervoMed (CRVO) options fully vest?

The award vests over 36 months. The underlying shares vest in 36 monthly installments, each on the last calendar day of the month, beginning February 28, 2026, so the full grant is scheduled to vest after three years of this monthly schedule.

How many derivative securities does William Robert Elder own after this CervoMed (CRVO) grant?

After the reported grant, William Robert Elder beneficially owns 30,000 derivative securities directly. These are stock options giving him the right to acquire CervoMed common stock, as reflected in the post‑transaction holdings column of the Form 4 derivative securities table.